+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Gastrointestinal Drugs Market by Drug Category, Disease Type, Route of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5789600
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Gastrointestinal Drugs Market grew from USD 54.18 billion in 2023 to USD 57.27 billion in 2024. It is expected to continue growing at a CAGR of 5.78%, reaching USD 80.31 billion by 2030.

The scope of the gastrointestinal drugs market encompasses medications used for the treatment of all disorders related to the gastrointestinal tract, including conditions like GERD, IBS, and Crohn's disease. This market includes prescription drugs, OTC medications, and biologics. The necessity of gastrointestinal drugs is underscored by the high prevalence of digestive disorders globally, often linked to lifestyle changes, an aging population, and increasing incidences of chronic diseases. These drugs are primarily applied in healthcare settings, including hospitals, clinics, and even retail pharmacies, with end-users spanning patients, healthcare providers, and pharmaceutical companies.

Market growth is fueled by factors such as advancements in drug formulations, the increasing prevalence of gastrointestinal disorders, and evolving healthcare infrastructure. The growing patient preference for minimally invasive treatments is driving innovations in drug delivery systems. There's a surge in biotechnology-driven research, leading to the development of biologic therapies offering targeted solutions. However, market growth is challenged by stringent regulatory requirements, potential side effects associated with these medications, and high development and production costs. Amidst these challenges, emerging markets offer significant expansion opportunities due to growing healthcare awareness and improving healthcare facilities.

Pharmaceutical companies are recommended to invest in R&D focusing on novel drug delivery technologies and personalized medicine approaches to remain competitive. Advancements in microbiome research and the identification of microbiota-driven drug therapies present a promising area for innovation. Leveraging AI and big data for precision medicine can lead to more effective drug discovery processes. A continued focus on patient education and adherence strategies can enhance market penetration. Despite challenges, the gastrointestinal drugs market is poised for growth, offering avenues for innovation and expansion in response to evolving medical needs and technological progress. Engaging in strategic partnerships and collaborations can further mitigate risks related to market entry and operational barriers.

Understanding Market Dynamics in the Gastrointestinal Drugs Market

The Gastrointestinal Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing geriatric population, changing lifestyles and eating habits
    • Development in biologics and a rising number of rectal related diseases
    • Drug development and rising awareness
  • Market Restraints
    • Side effects associated with the drugs
  • Market Opportunities
    • R&D activities to enhance drug development
    • Technological advancements in the treatment process
  • Market Challenges
    • Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome

Exploring Porter’s Five Forces for the Gastrointestinal Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Gastrointestinal Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Gastrointestinal Drugs Market

External macro-environmental factors deeply influence the performance of the Gastrointestinal Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Gastrointestinal Drugs Market

The Gastrointestinal Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Gastrointestinal Drugs Market

The Gastrointestinal Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Gastrointestinal Drugs Market

The Gastrointestinal Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayer AG, Boehringer Ingelheim GmbH, Eisai Co., Ltd., Eli Lilly & Co., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novo Nordisk A/S, Sanofi S.A., SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Limited, and ZERIA Pharmaceutical Co.,Ltd..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Category
    • Acid Neutralizers
    • Anti-Inflammatory
    • Antiemetic & Antinauseants
    • Biologics
    • Laxatives & Anti-diarrheal
  • Disease Type
    • Gastroesophageal Reflux Disorder
    • Irritable Bowel Syndrome
  • Route of Administration
    • Oral
    • Parenteral
    • Rectal
  • End User
    • Hospital Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing geriatric population, changing lifestyles and eating habits
5.1.1.2. Development in biologics and a rising number of rectal related diseases
5.1.1.3. Drug development and rising awareness
5.1.2. Restraints
5.1.2.1. Side effects associated with the drugs
5.1.3. Opportunities
5.1.3.1. R&D activities to enhance drug development
5.1.3.2. Technological advancements in the treatment process
5.1.4. Challenges
5.1.4.1. Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Gastrointestinal Drugs Market, by Drug Category
6.1. Introduction
6.2. Acid Neutralizers
6.3. Anti-Inflammatory
6.4. Antiemetic & Antinauseants
6.5. Biologics
6.6. Laxatives & Anti-diarrheal
7. Gastrointestinal Drugs Market, by Disease Type
7.1. Introduction
7.2. Gastroesophageal Reflux Disorder
7.3. Irritable Bowel Syndrome
8. Gastrointestinal Drugs Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Rectal
9. Gastrointestinal Drugs Market, by End User
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Retail Pharmacies
10. Americas Gastrointestinal Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Gastrointestinal Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Gastrointestinal Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. GASTROINTESTINAL DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GASTROINTESTINAL DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. GASTROINTESTINAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GASTROINTESTINAL DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ACID NEUTRALIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETIC & ANTINAUSEANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES & ANTI-DIARRHEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 37. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 41. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 42. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 59. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 60. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 63. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 64. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 71. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 72. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 95. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 96. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 108. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 109. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 112. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 113. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 116. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 117. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 120. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 121. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 124. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 132. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 133. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 144. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 145. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 148. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 149. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 152. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 153. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 168. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 169. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 180. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 181. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Gastrointestinal Drugs Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd.
  • Eli Lilly & Co.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.
  • SFJ Pharmaceuticals Group
  • SRS Life Sciences Pte. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Limited
  • ZERIA Pharmaceutical Co.,Ltd.

Methodology

Loading
LOADING...

Table Information